Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use

Michael Copland, Paul Komenda, Eric D. Weinhandl, Peter A. McCullough, Jose Morfin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Mineral and bone disorder is a common complication of end-stage renal disease. Notably, hyperphosphatemia likely promotes calcification of the myocardium, valves, and arteries. Hyperphosphatemia is associated with higher risk for cardiovascular mortality and morbidity along a gradient beginning at 5.0 mg/dL. Among contemporary hemodialysis (HD) patients, mean serum phosphorus level is 5.2 mg/dL, although 25% of patients have serum phosphorus levels of 5.5 to 6.9 mg/dL; and 13%, >7.0 mg/dL. Treatment of hyperphosphatemia is burdensome. Dialysis patients consume a mean of 19 pills per day, half of which are phosphate binders. Medicare Part D expenditures on binders for dialysis patients approached $700 million in 2013. Phosphorus removal with thrice-weekly HD (4 hours per session) is ∼3,000 mg/wk. However, clearance is unlikely to counterbalance dietary intake, which varies around a mean of 7,000 mg/wk. Dietary restriction and phosphate binders are important interventions, but each has limitations. Dietary control is complicated by limited access to healthy food choices and unclear labeling. Meanwhile, adherence to phosphate binders is poor, especially in younger patients and those with high pill burden. Multiple randomized clinical trials show that intensive HD reduces serum phosphorus levels. In the Frequent Hemodialysis Network (FHN) trial, short daily and nocturnal schedules reduced serum phosphorus levels by 0.6 and 1.6 mg/dL, respectively, relative to 3 sessions per week. A similar effect of nocturnal HD was observed in an earlier trial. In the daily arm of the FHN trial, intensive HD significantly lowered estimated phosphate binder dose per day, whereas in the nocturnal arm, intensive HD led to binder discontinuation in 75% of patients. However, intensive HD appears to have no meaningful effects on serum calcium and parathyroid hormone concentrations. In conclusion, intensive HD, especially nocturnal HD, lowers serum phosphorus levels and decreases the need for phosphate binders.

Original languageEnglish (US)
Pages (from-to)S24-S32
JournalAmerican Journal of Kidney Diseases
Volume68
Issue number5
DOIs
StatePublished - Nov 1 2016

Fingerprint

Minerals
Renal Dialysis
Phosphates
Bone and Bones
Phosphorus
Hyperphosphatemia
Serum
Dialysis
Medicare Part D
Health Expenditures
Parathyroid Hormone
Chronic Kidney Failure
Myocardium
Appointments and Schedules
Randomized Controlled Trials
Arteries
Calcium
Morbidity
Food
Mortality

Keywords

  • calcium
  • Chronic kidney disease
  • cinacalcet
  • daily dialysis
  • end stage renal disease (ESRD)
  • Frequent Hemodialysis Network
  • home dialysis
  • intensive hemodialysis
  • mineral and bone disorder (MBD)
  • nocturnal hemodialysis
  • parathyroid hormone
  • phosphate binder
  • phosphorus
  • review
  • secondary hyperparathyroidism
  • short daily hemodialysis
  • vascular calcification

ASJC Scopus subject areas

  • Nephrology

Cite this

Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use. / Copland, Michael; Komenda, Paul; Weinhandl, Eric D.; McCullough, Peter A.; Morfin, Jose.

In: American Journal of Kidney Diseases, Vol. 68, No. 5, 01.11.2016, p. S24-S32.

Research output: Contribution to journalArticle

Copland, Michael ; Komenda, Paul ; Weinhandl, Eric D. ; McCullough, Peter A. ; Morfin, Jose. / Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use. In: American Journal of Kidney Diseases. 2016 ; Vol. 68, No. 5. pp. S24-S32.
@article{cc9d38b8deec47e5bcf9e462307d5318,
title = "Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use",
abstract = "Mineral and bone disorder is a common complication of end-stage renal disease. Notably, hyperphosphatemia likely promotes calcification of the myocardium, valves, and arteries. Hyperphosphatemia is associated with higher risk for cardiovascular mortality and morbidity along a gradient beginning at 5.0 mg/dL. Among contemporary hemodialysis (HD) patients, mean serum phosphorus level is 5.2 mg/dL, although 25{\%} of patients have serum phosphorus levels of 5.5 to 6.9 mg/dL; and 13{\%}, >7.0 mg/dL. Treatment of hyperphosphatemia is burdensome. Dialysis patients consume a mean of 19 pills per day, half of which are phosphate binders. Medicare Part D expenditures on binders for dialysis patients approached $700 million in 2013. Phosphorus removal with thrice-weekly HD (4 hours per session) is ∼3,000 mg/wk. However, clearance is unlikely to counterbalance dietary intake, which varies around a mean of 7,000 mg/wk. Dietary restriction and phosphate binders are important interventions, but each has limitations. Dietary control is complicated by limited access to healthy food choices and unclear labeling. Meanwhile, adherence to phosphate binders is poor, especially in younger patients and those with high pill burden. Multiple randomized clinical trials show that intensive HD reduces serum phosphorus levels. In the Frequent Hemodialysis Network (FHN) trial, short daily and nocturnal schedules reduced serum phosphorus levels by 0.6 and 1.6 mg/dL, respectively, relative to 3 sessions per week. A similar effect of nocturnal HD was observed in an earlier trial. In the daily arm of the FHN trial, intensive HD significantly lowered estimated phosphate binder dose per day, whereas in the nocturnal arm, intensive HD led to binder discontinuation in 75{\%} of patients. However, intensive HD appears to have no meaningful effects on serum calcium and parathyroid hormone concentrations. In conclusion, intensive HD, especially nocturnal HD, lowers serum phosphorus levels and decreases the need for phosphate binders.",
keywords = "calcium, Chronic kidney disease, cinacalcet, daily dialysis, end stage renal disease (ESRD), Frequent Hemodialysis Network, home dialysis, intensive hemodialysis, mineral and bone disorder (MBD), nocturnal hemodialysis, parathyroid hormone, phosphate binder, phosphorus, review, secondary hyperparathyroidism, short daily hemodialysis, vascular calcification",
author = "Michael Copland and Paul Komenda and Weinhandl, {Eric D.} and McCullough, {Peter A.} and Jose Morfin",
year = "2016",
month = "11",
day = "1",
doi = "10.1053/j.ajkd.2016.05.024",
language = "English (US)",
volume = "68",
pages = "S24--S32",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use

AU - Copland, Michael

AU - Komenda, Paul

AU - Weinhandl, Eric D.

AU - McCullough, Peter A.

AU - Morfin, Jose

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Mineral and bone disorder is a common complication of end-stage renal disease. Notably, hyperphosphatemia likely promotes calcification of the myocardium, valves, and arteries. Hyperphosphatemia is associated with higher risk for cardiovascular mortality and morbidity along a gradient beginning at 5.0 mg/dL. Among contemporary hemodialysis (HD) patients, mean serum phosphorus level is 5.2 mg/dL, although 25% of patients have serum phosphorus levels of 5.5 to 6.9 mg/dL; and 13%, >7.0 mg/dL. Treatment of hyperphosphatemia is burdensome. Dialysis patients consume a mean of 19 pills per day, half of which are phosphate binders. Medicare Part D expenditures on binders for dialysis patients approached $700 million in 2013. Phosphorus removal with thrice-weekly HD (4 hours per session) is ∼3,000 mg/wk. However, clearance is unlikely to counterbalance dietary intake, which varies around a mean of 7,000 mg/wk. Dietary restriction and phosphate binders are important interventions, but each has limitations. Dietary control is complicated by limited access to healthy food choices and unclear labeling. Meanwhile, adherence to phosphate binders is poor, especially in younger patients and those with high pill burden. Multiple randomized clinical trials show that intensive HD reduces serum phosphorus levels. In the Frequent Hemodialysis Network (FHN) trial, short daily and nocturnal schedules reduced serum phosphorus levels by 0.6 and 1.6 mg/dL, respectively, relative to 3 sessions per week. A similar effect of nocturnal HD was observed in an earlier trial. In the daily arm of the FHN trial, intensive HD significantly lowered estimated phosphate binder dose per day, whereas in the nocturnal arm, intensive HD led to binder discontinuation in 75% of patients. However, intensive HD appears to have no meaningful effects on serum calcium and parathyroid hormone concentrations. In conclusion, intensive HD, especially nocturnal HD, lowers serum phosphorus levels and decreases the need for phosphate binders.

AB - Mineral and bone disorder is a common complication of end-stage renal disease. Notably, hyperphosphatemia likely promotes calcification of the myocardium, valves, and arteries. Hyperphosphatemia is associated with higher risk for cardiovascular mortality and morbidity along a gradient beginning at 5.0 mg/dL. Among contemporary hemodialysis (HD) patients, mean serum phosphorus level is 5.2 mg/dL, although 25% of patients have serum phosphorus levels of 5.5 to 6.9 mg/dL; and 13%, >7.0 mg/dL. Treatment of hyperphosphatemia is burdensome. Dialysis patients consume a mean of 19 pills per day, half of which are phosphate binders. Medicare Part D expenditures on binders for dialysis patients approached $700 million in 2013. Phosphorus removal with thrice-weekly HD (4 hours per session) is ∼3,000 mg/wk. However, clearance is unlikely to counterbalance dietary intake, which varies around a mean of 7,000 mg/wk. Dietary restriction and phosphate binders are important interventions, but each has limitations. Dietary control is complicated by limited access to healthy food choices and unclear labeling. Meanwhile, adherence to phosphate binders is poor, especially in younger patients and those with high pill burden. Multiple randomized clinical trials show that intensive HD reduces serum phosphorus levels. In the Frequent Hemodialysis Network (FHN) trial, short daily and nocturnal schedules reduced serum phosphorus levels by 0.6 and 1.6 mg/dL, respectively, relative to 3 sessions per week. A similar effect of nocturnal HD was observed in an earlier trial. In the daily arm of the FHN trial, intensive HD significantly lowered estimated phosphate binder dose per day, whereas in the nocturnal arm, intensive HD led to binder discontinuation in 75% of patients. However, intensive HD appears to have no meaningful effects on serum calcium and parathyroid hormone concentrations. In conclusion, intensive HD, especially nocturnal HD, lowers serum phosphorus levels and decreases the need for phosphate binders.

KW - calcium

KW - Chronic kidney disease

KW - cinacalcet

KW - daily dialysis

KW - end stage renal disease (ESRD)

KW - Frequent Hemodialysis Network

KW - home dialysis

KW - intensive hemodialysis

KW - mineral and bone disorder (MBD)

KW - nocturnal hemodialysis

KW - parathyroid hormone

KW - phosphate binder

KW - phosphorus

KW - review

KW - secondary hyperparathyroidism

KW - short daily hemodialysis

KW - vascular calcification

UR - http://www.scopus.com/inward/record.url?scp=84994852260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994852260&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2016.05.024

DO - 10.1053/j.ajkd.2016.05.024

M3 - Article

C2 - 27772640

AN - SCOPUS:84994852260

VL - 68

SP - S24-S32

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -